CellaVision to acquire RAL Diagnostics

CellaVision AB (publ) has signed an agreement to acquire the French company RAL Diagnostics (RAL).

RAL manufactures sample preparation products in hematology, pathology, cytology and microbiology. The company’s reagents help to identify cell and tissue morphology, parasites and bacteria that are necessary to diagnose many illnesses.

CellaVision is an innovative, global medical technology company that develops and sells leading systems for routine analysis of blood and other body fluids in health care services. CellaVision’s head office is located in Lund and the company has a direct presence in more than 30 countries. CellaVision’s share is listed on Nasdaq, Stockholm.

CellaVision was advised by Mannheimer Swartling in the transaction.

Related news

Impilo and KKR has entered into a strategic partnership together with management in rare disease platform Immedica Pharma

HMS Networks has completed the acquisition of Red Lion Controls and carried out a directed share issue

Bluestep Bank completes cross-border merger with Norway’s Bank2

Fortnox acquires Boardeaser and VisualBy

Popular search terms

Cookies

This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.